Zellis Group agrees to acquire Benify in transformational global benefits software combination

No Comments
Apax

Zellis Group agrees to acquire Benify in transformational global benefits software combination

  • Benify to be combined with Zellis Group’s benefits administration and employee engagement software business, Benefex. Together, Benefex and Benify will offer enhanced product and services capabilities to customers globally
  • Complementary geographic footprints improve ability to serve customers in the fragmented benefits administration and employee engagement software segment

Zellis Group (or the “Company”), a portfolio company of funds advised by Apax Partners LLP (“Apax”) providing HR, payroll, and benefits administration software, today announced that it has reached a definitive agreement to acquire Benify, a provider of employee benefits administration software, from Vitruvian Partners. As part of the transaction, Benify will be combined with Zellis Group’s benefits administration and employee engagement software business, Benefex, and Vitruvian Partners will become a minority investor in Zellis Group alongside the Apax Funds.

Together, Benefex and Benify will create a leading global benefits, reward, recognition, and employee engagement software provider with an enhanced value proposition to customers globally. Benefex and Benify are highly complementary, and this acquisition creates a truly global solution, powered by an expanded geographic network, a strengthened product portfolio, and a broader range of services. The combination will allow customers to benefit from a deeper suite of platform integrations across HR, Payroll and Benefit Carriers. This acquisition comes at a time when global employers are accelerating investment in technology to create a single global experience across benefits and reward, underpinned by a focus on eliminating administration and ensuring compliance.

Benefex was acquired by the Zellis Group in 2018, and has since experienced rapid global growth, powering exceptional employee experiences for customers through its modern benefits management, brokering, and engagement offerings.

Founded in 2004, Benify is a pioneer of benefits administration software services and today offers best-in-class benefits and total rewards solutions via a globally enabled SaaS platform. Following a long-term growth investment programme under Vitruvian ownership since 2011, Benify has evolved from a Sweden-focussed business into a global business within its field.

Combined, Benefex and Benify will support c.3,000 companies across more than 100 countries to transform and align the experiences of more than 5 million employees through their modern benefits, wellbeing, broking, rewards and recognition, and communications offerings. Together, the two businesses will be better able to enhance employee experiences across the globe.

Matt Macri-Waller, CEO of Benefex said: “We’re excited by the opportunity that this combination provides for new and crucially current customers of both Benify and Benefex. Together we share a common goal of powering a truly global and exceptional employee experience for our customers and this acquisition develops the global capabilities of our products and services, whilst bringing together the depth of talent that sits across both organisations.”

John Petter, CEO of Zellis Group, added: “This represents an exciting next chapter for the Zellis Group and is an early demonstration of the commitment of the Apax Funds to our continued growth.”

Joakim Alm, CEO of Benify commented: “We look forward to joining Zellis Group and Benefex to create a leading player in HCM software. By combining our respective strengths, we will further expand our products, services and value to our customers and their employees. The transaction is a testament to Benify’s track record of achieving profitable growth through delivering world class solutions to our customers and the hard work and dedication of our entire team. We are grateful for the support we have received from Vitruvian in accelerating our international growth journey over the past decade.”

Adam Garson, Principal at Apax, said: “When the Apax Funds invested in the Zellis Group, we identified an opportunity to accelerate the growth of Benefex and help establish the business as a leading provider in the large, fragmented, and growing global benefits administration software segment. The combination with Benify is an important milestone in this growth journey and we look forward to working with the teams at Zellis Group, Benefex, and Benify as the two companies come together.”

Jussi Wuoristo, Partner at Vitruvian Partners, said: “We are delighted with Benify’s remarkable growth journey to date which has been made possible thanks to the continued commitment of the Benify management team, its founders and its employees over the years. Since our investment, Benify has organically multiplied in size many times over and thus emerged as a strong global player in its field. We are excited to be able to continue our support to the company as a minority shareholder of Zellis Group and are highly enthusiastic about the road ahead.”

Zellis Group was advised by Arma Partners, Evercore, and Kirkland & Ellis. Benify and Vitruvian were advised by Deutsche Bank and Bird & Bird. Completion of the proposed transaction is subject to customary closing conditions. Financial terms were not disclosed.

Categories: News

Tags:

Leinco Technologies Inc. Acquires QED Biosciences, Leading Provider of Antibodies, Related Reagents, and Development Services

Ampersand

Leinco Technologies Inc. Acquires QED Biosciences, Leading Provider of Antibodies, Related Reagents, and Development Services

Strategic acquisition will enable Leinco to expand its portfolio of antibody capabilities used globally for research and diagnostics.

St. Louis, MO – September 3, 2024 – Leinco Technologies (“Leinco”), a trusted source of high-quality primary and secondary antibodies, recombinant proteins, biological buffers, assay substrates and IVD raw materials, today announced its acquisition of Genovis-owned QED Biosciences (“QED”), a leading provider of antibodies, kits, and recombinant proteins and antigens catering to the diverse needs of the IVD and research communities. In addition, QED complements Leinco’s suite of antibody development and other services, strategically targeting the IVD and research sectors.

Founder and CEO of Leinco Technologies, Pat Leinert Sr., comments, “We are thrilled to integrate Genovis’s antibody business into our portfolio and look forward to serving all of QED’s current customers. This acquisition strengthens our position in the antibody market by allowing us to offer an even broader range of innovative, high-quality products to our global customers. We look forward to building on Genovis’ legacy of excellence and delivering these unique antibodies to researchers and clinicians worldwide.”

Backed by private equity firm Ampersand Capital Partners (“Ampersand”), Leinco Technologies has built a reputation for delivering high-quality antibodies used in cutting-edge research and diagnostic applications. Ampersand Operating Partner and Leinco Chairman, Frank Witney, adds, “We look forward to integrating QED’s exceptional capabilities and high-quality products and services into the Leinco portfolio. The addition of QED positions Leinco well for continued growth as a global leader serving the antibody market.”

“We are pleased to have found a strong partner in Leinco Technologies to take over our antibody business,” said Fredrik Olsson, CEO of Genovis. “We believe that under Leinco’s ownership, the antibody business will thrive and continue to serve its customers with the same commitment to quality and innovation.”

The acquisition of QED strengthens Leinco Technologies’ strategic growth strategy in the life science and IVD raw material markets. This move builds upon Leinco’s recent investments, including:

  • Expansion of Catalog Offerings: Providing researchers with a wider range of high-quality reagents including antibodies and recombinant proteins
  • Launch of Rabbit Monoclonal Antibody Development Services: Addressing the growing demand for advanced antibody solutions
  • Addition of Downstream Site-Specific Conjugation: Delivering precise and targeted antibody modifications
  • Launch of Enhanced CHO Cell Expression System: Achieving 3-6 grams per liter protein expression levels

These recent strategic investments solidify Leinco’s commitment to driving innovation and empowering researchers with cutting-edge tools to enable groundbreaking discoveries in life science and diagnostics.

 



 

About Leinco Technologies Inc.

Headquartered in St. Louis, Missouri, Leinco Technologies is a biotechnology company that was founded in 1992 as a specialty manufacturer of early discovery research products including antibodies, recombinant proteins, ELISA kits, second step reagents and many other life science research products. Shortly thereafter, Leinco also established itself as a premier provider of IVD raw materials and custom manufacturing or discovery services with a focus on monoclonal antibodies and recombinant proteins. Our innovative products and services are used all over the world to augment the early discovery processes in life science research, diagnostics and development of protein therapeutics. For additional information, visit Leinco.com or follow us on LinkedIn.

About Genovis

Headquartered in Kävlinge, Sweden, Genovis offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Genovis enzyme products, known as SmartEnzymes, are used by scientists all over the world and the innovative product formats facilitate development and quality control of biological drugs. Additionally, Genovis provides the highest quality polyclonal and monoclonal catalogue antibodies and novel bespoke antibody services for development and bulk manufacturing.

About Ampersand Capital Partners

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. For additional information, visit Ampersandcapital.com or follow us on LinkedIn.

Categories: News

Tags:

819 Capital Partners invests in UK-based Vidiia Ltd.

819 Capital Partners

819 Capital Partners has recently invested in Vidiia Ltd. from 819 Evergreen Fund, alongside a bio-scientist entrepreneur, the University of Surrey and Brunel University London.

 

 

 

Accelerating the growth strategy

Vidiia commercialises a fast and accurate molecular diagnostic testing platform with built-in Artificial Intelligence (AI). The new funding will be used to accelerate the company’s growth strategy.

David Rimer, CEO and Founder of Vidiia: “With the funds we can implement our growth strategy, which aims to commercialise existing assays ready for market, develop new assays with universities and enhance our AI powered testing platform. Vidiia’s Assay Accelerator service, pulls tests off university benches and gets them to market, which we have now proven several times.”

Strong testing platform

Vidiia has a strong testing platform, which is explained by Dr Nick Hutchings, one of the investors in this round: “Assays are reproducible tools that allow us to understand medicine and biology at a molecular level. I am excited to join Vidiia and help scientists to develop and commercialise new assays on the world class Vidiia platform.”

Sven Kempers, director at 819 Capital Partners, expresses trust in Vidiia’s platform and team: “Vidiia’s technology provides many testing options for rapid diagnoses. We are confident that the team will successfully execute the growth strategy.”

Academic validation

Vidiia has strong support from academic institutions, such as Brunel University London and University of Surrey.

Dr Averil Horton – Head of Business Development and Innovation, Brunel University London – explains: “The Vidiia Assay Development Programme has enabled Brunel to place innovative bio-science IP within a structured framework to commercialisation. Their methodology and AI powered testing platform mean they have the end-to-end knowledge and tools for success.”

Professor Lisa Collins – Pro-Vice-Chancellor, Research and Innovation at the University of Surrey – said: “It is fantastic to see the groundbreaking research of our scientists being brought to market with the help of Vidiia. It is important that the scientific community and industry partners continue to work together to develop innovative testing products to identify infectious diseases.”

Professor Roberto La Ragione – Professor of Veterinary Microbiology and Pathology, School of Veterinary Medicine, and Head of the School of Biosciences at the University of Surrey – said: “Infectious diseases remain a global threat to human and animal health, and our economies. Funding is necessary to enable Vidiia and our scientists to continue our work in developing highly accurate and rapid tests to prevent the next pandemic.”

Hands-on experience

David Rimer, concludes that investment brings more than just the funding: “We are delighted to be working with 819 and Dr Nick Hutchings. Both parties bring the crucial hands-on experience and connections that Vidiia were looking for. The continued support from our university partners also provides a significant boost beyond financial investment.”

819 Capital Partners invested in Vidiia Ltd. from 819 Evergreen Fund.

More information about Vidiia Ltd. on: https://vidiia.com/

Categories: News

Tags:

Aryza acquires Axcess Consulting

Pollenstreet

Pollen Street Capital are pleased to announce that Aryza has acquired Axcess Consulting Pty Ltd (“Axcess”), an Australian headquartered provider of loan management software to blue chip financial services companies across Australia, UK, Ireland, New Zealand, Asia and North America.

Founded in Geelong in 1991, the Axcess platform is a scalable SaaS offering designed to help banks, non-bank lenders, and debt purchasers manage loan origination, underwriting, servicing and investment portfolio management using a single consolidated platform.

Aryza’s acquisition of Axcess will expand its reach in the APAC region, a geography with significant potential for further expansion and cross-selling of Aryza’s broader lending and debt management software solutions. Axcess and its customers will benefit from being part of the Aryza group, tapping into the product innovation within Aryza’s existing loan management software division as well as the group’s global reach.

The transaction, which is Aryza’s 11th acquisition since 2018, supports its mission to be the leading global provider of software solutions across the entire credit-debt lifecycle. Aryza has built a strong end-to-end proposition targeting administratively intense, regulated and data driven processes across lending and debt management, delivering significant gains in efficiency and effectiveness for its clients.

Colin Brown, CEO at Aryza, commented:

“This strategic move aligns perfectly with our mission to expand our global footprint and deliver innovative financial solutions to a wider audience. Axcess Consulting’s expertise and local market knowledge complement Aryza’s technological capabilities, creating a powerful synergy that will enhance our service offerings and provide greater value to our clients. We look forward to driving growth and innovation in the financial services industry across Australia.”

Anastasia Kovaleva, Partner at Pollen Street Capital, added:

“We are pleased to welcome Axcess to the Aryza group and to add a high-calibre name to our footprint in the APAC region, which we see as an exciting opportunity for further growth. Axcess brings 30+ years of experience in LMS in the region, enhancing Aryza’s product offering and customer reach. The acquisition is a continuation of Aryza’s strategy to become a global leader in automating processes across the credit cycle.”

Categories: News

Tags:

Acquisition Spaans Babcock

Anders Invest

Anders Invest has acquired screw pump manufacturer Spaans Babcock from Balk. The company has an annual turnover of €20 to €25 million and employs over 100 people.

Spaans Babcock engineers, produces, builds and installs screw pumps, screw generators, grids and aeration for wastewater treatment plants, pumping stations and hydroelectric power plants. The company is over 125 years old and was founded in 1897 by the Spaans family. In 1974, the company became part of the FKI Group Ltd., which also had a Babcock company in its group, and the current company name was created. In 1995, the company was acquired by the Alpha Group International.

The company realises the majority of its turnover with screw pumps, aerators and hydro turbines, in which niche the company is the global market leader. A large production location is located in Balk where the screw pumps are produced using CNC-controlled machines and welding robots. The screw pump distinguishes itself from other pumping techniques because of its capacity, lifespan, insensitivity to contaminated liquids and energy efficiency. In addition, the screw is fish-friendly and maintains the biological balance in purification plants because the pump has no destructive effect on the composition of the liquid. In addition to the branch in Balk, there are branches in England and Canada/United States.

The end customers are generally (waste) water purification companies, water boards (for example polder pumping stations) and companies active in the construction or operation of sewage treatment. With its own sales offices in England (Heywood) and Canada (Ontario), Spaans Babcock supplies its products worldwide.

The shares in Spaans Babcock were acquired from Alpha Group International.  The Alpha Group is an investment vehicle of Mr. Nolst Trenité and Mr. Eijt. Mr. Eijt is general manager at Spaans Babcock and will remain as general manager and shareholder.

Categories: News

Tags:

Tikehau Capital completes the sale of its stake in Preligens to Safran

Tikehau

Tikehau Capital, the global alternative asset manager, today completes the acquisition by Safran of its stake in Preligens, a world leader in artificial intelligence (AI) for aerospace and defence, for an enterprise value of €220 million. Following an exclusive negotiation process that began in June 2024, Tikehau Capital is selling its stake in Preligens to Safran.

Founded in 2016 by two French engineers, Preligens provides field-proven Artificial Intelligence (AI) analysis solutions for high-end imagery, full-motion video and acoustic signals.

Tikehau Capital’s investment in November 2020 has played a key role in accelerating the growth of Preligens, which has increased revenues tenfold (from €3 million to nearly €30 million), expanded operations in the US and Asia, and now employs around 250 people, including 140 R&D engineers. This sale is the first divestment of Brienne III, the first vintage of the Group’s private equity strategy dedicated to cybersecurity. This strategy has raised almost 4001million euros over its two vintages and has now invested 150 million euros in 16 companies including Trustpair, Chapsvision and Egerie in France and VMRay in Germany. This transaction generates a MOIC of 2.4x and a gross IRR of 30.4%2. 1Brienne III raised €175 million, making it Europe’s largest fund dedicated to cybersecurity. The next vintage announced a closing of €200 million in October 2023, exceeding the final size of the predecessor fund.

22.1x net MOIC and 18% net IRR 1 PRESS RELEASE  PARIS, 2 SEPTEMBER 2024 PRESS CONTACTS: Tikehau Capital: Valérie Sueur +33 1 53 59 03 64 UK – Prosek Partners: Philip Walters – +44 (0) 7773 331 589 USA – Prosek Partners: Trevor Gibbons – +1 646 818 9238 press@tikehaucapital.com SHAREHOLDER AND INVESTOR CONTACTS: Louis Igonet – +33 1 40 06 11 11 Théodora Xu – +33 1 40 06 18 56 shareholders@tikehaucapital.com

ABOUT TIKEHAU CAPITAL: Tikehau Capital is a global alternative asset management group with €46.1 billion of assets under management (at 30 June 2024). Tikehau Capital has developed a wide range of expertise across four asset classes (private debt, real assets, private equity and capital markets strategies) as well as multi-asset and special opportunities strategies. Tikehau Capital is a founder-led team with a differentiated business model, a strong balance sheet, proprietary global deal flow and a track record of backing high quality companies and executives. Deeply rooted in the real economy, Tikehau Capital provides bespoke and innovative alternative financing solutions to companies it invests in and seeks to create long-term value for its investors, while generating positive impacts on society. Leveraging its strong equity base (€3.1 billion of shareholders’ equity at 30 June 2024), the firm invests its own capital alongside its investor-clients within each of its strategies. Controlled by its managers alongside leading institutional partners, Tikehau Capital is guided by a strong entrepreneurial spirit and DNA, shared by its 762 employees (at 30 June 2024) across its 17 offices in Europe, Middle East, Asia and North America. Tikehau Capital is listed in compartment A of the regulated Euronext Paris market (ISIN code: FR0013230612; Ticker: TKO.FP). For more information, please visit: www.tikehaucapital.com.

DISCLAIMER: The strategy mentioned in this press release is reserved for professional investors and is managed by Tikehau Investment Management SAS, a portfolio management company approved by the AMF since 19/01/ 2007 under the number GP-07000006. Non-contractual document intended exclusively for journalists and media professionals. The information is provided for the sole purpose of enabling them to have an overview of the transactions, whatever the use they make of it, which is exclusively a matter of their editorial independence, for which Tikehau Capital declines all responsibility. This document does not constitute an offer to sell securities or investment advisory services. This document contains only general information and is not intended to represent general or specific investment advice. Past performance is not a reliable indicator of future results and targets are not guaranteed. Certain statements and forecasted data are based on current forecasts, prevailing market and economic conditions, estimates, projections and opinions of Tikehau Capital and/or its affiliates. Owing to various risks and uncertainties actual results may differ materially from those reflected or expected in such forward-looking statements or in any of the case studies or forecasts. Tikehau Capital accepts no liability, direct or indirect, arising from the information contained in this document. Tikehau Capital shall not be liable for any decision taken on the basis of any information contained in this document. All references to Tikehau Capital’s advisory activities in the US or with respect to US persons relate to Tikehau Capital North America. 2

Categories: News

Tags:

Biotalys Receives Approval for Large-Scale Demonstration Trials of EVOCA in the Netherlands

GIMV

Ghent, BELGIUM – 2 September 2024, 07:00 CEST – Biotalys (Euronext: BTLS) an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, today announced it received approval by the Dutch regulator CTGB (College voor de Toelating van Gewasbeschermingsmiddelen en Biociden) for large-scale demonstration trials in greenhouses of its first biofungicide candidate, EVOCA™*. Importantly, the harvested fruits and vegetables can be sold for human consumption.

Jeannette Vriend, Plant protection specialist at Dutch growers association Glastuinbouw Nederland, said: “We are very pleased that this innovative technology can now be tested at large scale by growers. Given the many challenges to adequately control fungal diseases in tomatoes, cucumbers and strawberries, due to a sharply shrinking crop protection product package, we really need the acceleration of new, green solutions. These trials offer an ideal opportunity to properly implement such solutions in these high-value integrated crops.”

The CTGB granted Biotalys the approval to test EVOCA against powdery mildew in 40 hectares of tomatoes, 20 hectares of cucumbers and 10 hectares of strawberries. Produce from these greenhouse trials is allowed to be sold for human consumption, an exemption to standard practices requiring crop destruction when a crop protection product is used that has not yet received regulatory approval.**

*download the complete PR

Categories: News

Tags:

Yellowtail Conclusion acquires Fortrum

NPM Capital

Yellowtail Conclusion is acquiring Fortrum, which will give it a significant edge in the area of mortgage and risk management. The acquisition will allow Yellowtail Conclusion to expand the range of services it offers its clients and to provide more innovative solutions. Yellowtail Conclusion is part of the Conclusion ecosystem, an NPM participation.

Yellowtail Conclusion acquires Fortrum

 

Fortrum is based in Houten and was established in 2018 by Michel van der Sluis, Jaap van Raak, Simon Collingridge, and Tony Ward. Fortrum offers consultancy services in the area of risk, governance and compliance and is also specialised in carrying out due diligence, for which it developed the FortApp. The acquisition adds a group of expert professionals to the Yellowtail Conclusion team and offers major benefits in terms of scale and synergy.

 

This strategic acquisition will enable clients to benefit from the combined expertise and innovative solutions offered by Fortrum, Yellowtail Conclusion, and Davinci Conclusion. Their collaboration will make it possible for all three organisations to offer an unparalleled package of services and software solutions to clients in the mortgage and credit market, thereby covering the entire value chain.

 

More information is available at the Yellowtail Conclusion website.

Categories: News

Tags:

Acquisition Spaans Babcock

Anders Invest

Anders Invest has acquired screw pump manufacturer Spaans Babcock from Balk. The company has an annual turnover of €20 to €25 million and employs over 100 people.

Spaans Babcock engineers, produces, builds and installs screw pumps, screw generators, grids and aeration for wastewater treatment plants, pumping stations and hydroelectric power plants. The company is over 125 years old and was founded in 1897 by the Spaans family. In 1974, the company became part of the FKI Group Ltd., which also had a Babcock company in its group, and the current company name was created. In 1995, the company was acquired by the Alpha Group International.

The company realises the majority of its turnover with screw pumps, aerators and hydro turbines, in which niche the company is the global market leader. A large production location is located in Balk where the screw pumps are produced using CNC-controlled machines and welding robots. The screw pump distinguishes itself from other pumping techniques because of its capacity, lifespan, insensitivity to contaminated liquids and energy efficiency. In addition, the screw is fish-friendly and maintains the biological balance in purification plants because the pump has no destructive effect on the composition of the liquid. In addition to the branch in Balk, there are branches in England and Canada/United States.

The end customers are generally (waste) water purification companies, water boards (for example polder pumping stations) and companies active in the construction or operation of sewage treatment. With its own sales offices in England (Heywood) and Canada (Ontario), Spaans Babcock supplies its products worldwide.

The shares in Spaans Babcock were acquired from Alpha Group International.  The Alpha Group is an investment vehicle of Mr. Nolst Trenité and Mr. Eijt. Mr. Eijt is general manager at Spaans Babcock and will remain as general manager and shareholder.

Categories: News

Tags:

Investment in HTC Group

Anders Invest

Anders Invest has acquired a minority stake in HTC Group from Waddinxveen. HTC is the Dutch market leader in speed gates and employs over 80 people.
HTC is known for its high-quality products and innovative custom solutions. For example, the company has introduced mobile speed gates for temporary applications and produces speed gates with safety standards up to and including RC5. HTC has developed a product-as-a-service model and is investing in sustainability by developing the circular speed gate.
The company’s head office is located in Waddinxveen, where the production and assembly of the speed gates also takes place. From this location, the company carries out service and maintenance work with a nationwide network. HTC has its own engineering branch for the development of its products. Sales take place from the Netherlands and through a dealer network in Europe. Its customers are parking managers, government institutions, installers and homeowners’ associations.
The shares in HTC were acquired from Peter Thun. In addition to Anders Invest, operational director Robert-Jan Karsman has joined as a shareholder. Peter will remain as general manager and majority shareholder.

Categories: News

Tags: